. Author manuscript; available in PMC: 2020 Apr 1.

Published in final edited form as: J Heart Lung Transplant. 2018 Oct 1;38(4):408–417. doi: 10.1016/j.healun.2018.09.021

Table 2.

INTERMACS patient profiles at enrollment into the MedaMACS study track with functional status and quality of life.

	Profile 4 (N=21)	Profile 5 (N=49)	Profile 6 (N=76)	Profile 7 (N=15)
Age (years)	58 ± 10	60 ± 11	59 ± 11	57 ± 9
Ejection fraction (%)	21 ± 8	21 ± 7	21 ± 7	22 ± 6
NT-pro BNP (pg/ml)	6496 ± 4617	6407 ± 6952	4997 ± 3908	3564 ± 5946
Six minute walk (m)^*	166 ± 143	143 ± 140	239 ± 154	212 ± 192
Gait speed (m/s)^*	0.8 ± 0.3	0.9 ± 0.5	1.1 ± 0.4	1.4 ± 0.3
Peak VO2 (mL/kg/min)^*	9.8 ± 4.1	10.9 ± 3.1	13.2 ± 5.5	12.9 ± 1.0
EuroQol 5D Index^*	0.52 ± 0.21	0.70 ± 0.15	0.72 ± 0.19	0.73 ± 0.19
EuroQol VAS^*	45 ± 20	54 ± 21	59 ± 21	60 ± 17
KCCQ score	52 ± 10	52 ± 12	50 ± 8	48 ± 14

P<0.05 for comparison across INTERMACS Patient Profiles

VO2=Oxygen consumption, VAS=Visual Analog Scale, KCCQ=Kansas City Cardiomyopathy Questionnaire